Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13842050 | 0.86 | PPARA (0.31) | — | |
| SCHEMBL8876640 | 0.85 | PPARA (0.33) | — | |
| SCHEMBL75036 | 0.80 | APLNR (0.35) | APP | |
| SCHEMBL13130047 | 0.80 | APP (0.33) | APP | |
| SCHEMBL13381326 | 0.78 | APP (0.32) | APP | |
| SCHEMBL4089453 | 0.77 | — | — | |
| SCHEMBL23027447 | 0.77 | TSHR (0.39) | — | |
| SCHEMBL14425473 | 0.76 | APP (0.31) | APP | |
| SCHEMBL28526092 | 0.76 | CA2 (0.32) | APP | |
| SCHEMBL914200 | 0.76 | APP (0.31) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102070636-A | Preparation method of penciclovir | UNIV ZHEJIANG | 2011-05-25 | — | — | CN | claimed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | claimed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250354079-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING MEDIUM | RESONAC CORPORATION (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-119684140-A | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250000797-A1 | NANOMATERIALS | GUIDE THERAPEUTICS, LLC | 2025-01-02 | — | — | US | disclosed |
| CN-115175894-B | Nanomaterial for the preparation of a nanoparticle | 盖德治疗有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240101759-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | RESONAC CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| WO-2023238906-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | 株式会社レゾナック | 2023-12-14 | — | — | WO | disclosed |
| EP-4103542-A1 | NANOMATERIALS | Guide Therapeutics, LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | QUADEX PHARMACEUTICALS, LLC | 2006-06-22 | — | — | US | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6579981-B1 | Treating herpes virus | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-17 | — | — | US | disclosed |
| US-6573378-B1 | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-03 | — | — | US | disclosed |
| US-5075445-A | GUANINE DERIVATIVES | BEECHAM GROUP P.L.C. (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0141927-A2 | Antiviral guanine derivatives | BEECHAM GROUP PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135464-A1 | Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues | DCTD, ADA, TYMP | BRD4 4757/4885APP 2476/4885ESR2 4708/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | BRD4 4708/4885APP 599/4885ESR2 2012/4885 |
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | BRD4 163/4885APP 4883/4885ESR2 3802/4885 |
| US-20250000797-A1 | NANOMATERIALS | POLRMT, PHOSPHO1, FABP1 | BRD4 4375/4885APP 3528/4885ESR2 2479/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | BRD4 4741/4885APP 2410/4885ESR2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.